1. Canada Stocks

  2. •

    Utilities

  3. •

    Regulated Electric
Emera Incorporated

Emera Incorporated

EMA
Emera IncorporatedUS flagNew York Stock Exchange
53.58
USD
-0.76
- -
16.39BMarket Cap
Emera Incorporated
EMA
(New York Stock Exchange)

Recent

price

53.58

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
14.06
17.06
16.48
16.82
20.52
19.1
25.01
29.18
28
25.46
22.2
22.43
28.53
27.6
24.9
29.33
29.65
Revenue per Share
1.67
1.99
1.77
1.64
2.84
2.72
1.33
1.25
3.05
2.76
3.78
1.98
3.55
3.57
1.71
3.39
3.3
Basic EPS, GAAP
-1.06
-0.6
-0.29
1.86
2.18
1.29
-0.16
-1.57
-2.03
-4.04
-3.98
-4.57
-6.33
-2.54
-1.75
-5.78
-6.15
Free Cash Flow per Basic Share
1.25
1.36
1.44
1.55
1.65
1.32
1.46
1.48
1.64
1.76
1.83
1.92
2.01
2.02
2.11
2.18
2.21
Dividend per Share
5.72
17.53
19.47
19.01
21.15
22.77
34
30.42
29.58
30.79
33.06
33.42
35.14
37.46
36.35
36.77
38.63
Book Value per Share
9.8
11.39
12.64
15.52
18.44
23.02
-0.62
3.23
4.47
7.34
10.14
11.8
15.06
17.5
20.79
21.37
23.64
Tangible Book Value per Share
114
121
125
133
143
146
171
213
233
240
248
257
266
274
289
299
301
Basic Weighted Avg Shares
1,606
2,064
2,059
2,230
2,939
2,789
4,277
6,226
6,524
6,111
5,506
5,765
7,588
7,563
7,200
8,776
8,913
Sales/Revenue/Turnover
19.44
15.38
16.83
18.25
22.71
18.21
12.98
22.78
21.43
22.53
21.29
16.13
22.43
23.72
18.12
23.36
23.2
Operating Margin (%)
232
263
294
314
342
352
593
851
928
911
899
915
959
1,060
1,165
1,298
1,314
Depreciation Expense
194
248
232
237
433
427
255
294
746
708
983
560
1,008
1,044
567
1,089
1,070
Net Income, GAAP
- -
- -
- -
14.5
20.06
17.06
- -
63.49
8.46
7.91
25.74
- -
15.49
10.91
- -
6.92
7.83
Effective Tax Rate (%)
12.06
12
11.26
10.62
14.73
15.31
5.96
4.72
11.43
11.59
17.85
9.71
13.28
13.8
7.88
12.41
12
Profit Margin (%)
234
192
-12
-369
288
1,229
-1,213
-1,420
-1,721
-1,680
-2,697
-1,742
-2,391
-836
-1,427
-2,238
410
Working Capital
3,115
3,274
3,257
3,364
3,660
4,416
14,268
13,140
14,292
13,679
12,339
14,196
15,744
17,689
18,173
18,453
21,206
LT Debt
1,531
1,824
2,278
2,897
3,705
4,334
6,816
7,204
8,358
8,601
9,238
10,150
11,441
12,088
13,291
13,396
14,204
Total Equity
- -
- -
- -
5.33
7.2
5.02
- -
2.31
5.41
5.15
3.56
- -
5.04
5.12
- -
5.61
5.3
Return on Invested Capital (%)
- -
- -
- -
5.42
7.26
6.88
- -
2.43
5.95
5.69
6.1
- -
5.71
6.13
- -
6.2
5.82
Return on Capital (%)
30.61
17.38
9.7
8.78
14.66
12.5
4.97
4.32
10.61
9.29
12.03
6.08
10.54
9.97
4.76
9.43
8.79
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2,835
3,008
2,751
LT Borrowings
17,809
18,453
21,206
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
1,422
1,422
1,422
Shares Outstanding
301
302
306
Market Capitalization
19,939
20,184
21,688

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
4,026
4,389
6,586
Cash, Cash Equivalents & STI
212
349
2,457
Accounts Receivable, Net
963
1,265
1,110
Inventories
850
821
806
Total Current Liabilities
6,276
6,627
6,176
Payables & Accruals
1,813
2,333
1,674
ST Debt
2,835
3,008
2,751
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.83%
7.8%
0.79%
Free Cash Flow
139.67%
43.78%
242.57%
Net Income, GAAP
24.94%
17.38%
92.06%
Sales/Revenue/Turnover
14.06%
10.62%
21.89%
Total Cash Common Dividend
13.99%
7.11%
7.06%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,018
1,617
1,802
1,763
7,200
2025
2,676
1,988
2,106
2,006
8,776
2026
2,813
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.73
0.45
0.01
- -
1.71
2025
1.96
0.45
0.76
- -
3.39
2026
1.85
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.53
0.53
0.52
- -
2.11
2025
0.53
0.53
0.55
- -
2.18
2026
0.56
- -
- -
- -
- -
Similar Companies
PJSC TNS Energo Yaroslavl (YRSB.ME)
PJSC Territorial Generating Company No. 1 (TGKA.ME)
CLP Holdings Limited (CLPHY)
PPL Corporation (PPL)
Guangxi Guiguan Electric PowerCo.,Ltd. (600236.SS)
Romande Energie Holding S.A. (REHN.SW)
Business
Emera Incorporated, headquartered in Halifax, Nova Scotia, Canada, and founded in 1998, operates as a geographically diverse energy and services company investing in regulated electricity generation, transmission, and distribution as well as gas transmission and distribution across North America and the Caribbean, serving approximately 2.6 million utility customers through six electric and natural gas utilities. The company generates electricity via natural gas, solar, hydroelectric, coal, and biomass power plants; transmits and distributes electricity and natural gas; and provides energy marketing, trading, and asset management services, with key subsidiaries including Tampa Electric (Florida Electric Utility), Nova Scotia Power (Canadian Electric Utilities), Peoples Gas, and others organized into segments such as Florida Electric Utility, Canadian Electric Utilities, Other Electric Utilities, Gas Utilities and Infrastructure, and Other. Emera maintains 1,977 MW of installed renewable capacity and has achieved a 49% reduction in CO2 emissions since 2005 while focusing on decarbonization, decentralization, and digitalization trends. In recent developments, Emera unveiled a $20 billion five-year capital plan through 2029 in November 2025, with nearly 80% allocated to Florida for grid modernization, reliability enhancements, renewable integration, and technology updates supporting 7-8% rate base growth; sold its New Mexico Gas Company subsidiary to Bernhard Capital Partners in 2024 to optimize its portfolio and reallocate capital to high-growth markets; and completed its Peoples Gas rate case in 2025 alongside strong third-quarter adjusted EPS growth driven by Tampa Electric performance.

Company News

APIChatGPT

  • gurufocus.com

    Neuronata-R retains conditional approval in South Korea

  • businesswire.com

    CORRECTING and REPLACING Emera Declares Quarterly Dividends

  • gurufocus.com

    Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia

  • businesswire.com

    Emera Declares Quarterly Dividends

  • businesswire.com

    Emera Teleconference on August 7 to Discuss Q2 2026 Results

  • gurufocus.com

    Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

  • gurufocus.com

    Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

  • gurufocus.com

    Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

  • gurufocus.com

    WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market

  • gurufocus.com

    New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myel

  • gurufocus.com

    WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility

  • gurufocus.com

    Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

  • gurufocus.com

    Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

  • gurufocus.com

    Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patie

  • gurufocus.com

    BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026

  • gurufocus.com

    WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities

  • gurufocus.com

    Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

  • gurufocus.com

    Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026

  • businesswire.com

    Emera Inc. Announces Election of Directors

  • seekingalpha.com

    Emera Incorporated (EMA:CA) Shareholder/Analyst Call Transcript